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ARTICLE
Rapid optimisation of fragments and hits to
lead compounds from screening of crude
reaction mixtures
Lisa M. Baker 1,7, Anthony Aimon 2,3,7, James B. Murray1, Allan E. Surgenor 1, Natalia Matassova 1,
Stephen D. Roughley 1, Patrick M. Collins 2, Tobias Krojer 4, Frank von Delft 2,3,4,5 &
Roderick E. Hubbard 1,6✉
Fragment based methods are now widely used to identify starting points in drug discovery
and generation of tools for chemical biology. A significant challenge is optimization of these
weak binding fragments to hit and lead compounds. We have developed an approach where
individual reaction mixtures of analogues of hits can be evaluated without purification of the
product. Here, we describe experiments to optimise the processes and then assess such
mixtures in the high throughput crystal structure determination facility, XChem. Diffraction
data for crystals of the proteins Hsp90 and PDHK2 soaked individually with 83 crude reaction
mixtures are analysed manually or with the automated XChem procedures. The results of
structural analysis are compared with binding measurements from other biophysical tech-
niques. This approach can transform early hit to lead optimisation and the lessons learnt from
this study provide a protocol that can be used by the community.
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F
ragment-based discovery is now established as an effective
method in providing starting points to develop compounds
that can inhibit or activate the function of a protein1–3. The
central premise is that small (usually < 18 heavy atoms) com-
pounds have sufficient chemical functionality to bind, but are
small enough to fit into site(s) on a protein4. This contrasts with
the difficulties of identifying compounds that bind (hits) from
screening of libraries of larger compounds where additional
atoms on a compound may sterically block binding. There are
currently four molecules approved for treating patients5–8 that
were discovered with fragment-based methods and many other
clinical trials underway2.
The first step in fragment-based discovery is to screen a library
of fragment molecules against the protein target. There is a large
literature and experience of using a range of biophysical and
functional assays to perform such screening2,9. Most practitioners
use a biophysical assay (such as surface plasmon resonance (SPR),
protein or ligand-observed NMR or thermal shift measurements)
to detect binding of a fragment on a target and then subsequently
attempt to determine its structure (usually by X-ray crystal-
lography). An alternate approach (first demonstrated by
Abbott10, but successfully promoted by Astex11) is to screen
directly by determining the X-ray crystal structure of the protein
soaked with the fragment(s). This requires the protein to form
crystals with an accessible binding site and that can survive the
high concentration of the fragment. This approach has the
advantage of being able to detect very weak binding, and directly
characterises the fragment-binding pose. However, it has until
recently been very challenging to prepare the large number of
soaked individual crystals, and to handle the amount of data
collection and processing required to analyse the many thousands
of diffraction datasets needed to screen individual compounds in
a fragment library. The recent development of the XChem facility
at the Diamond synchrotron12–14 has greatly improved the
throughput, reliability and feasibility of performing such crys-
tallographic screening of fragment libraries, and now screening of
1000-member fragment libraries can be completed (and data
analysed) within a few days.
For most proteins, fragment-based screening can identify many
10 s (and in some cases, hundreds) of fragment hits15–18. The
issue then is identifying which of the hits to optimise, or how best
to analyse the structural information given by multiple binding
events. The usual practice is to explore the structure–activity
relationships (SAR) of the fragments by accessing (from com-
mercial vendors, from internal library collection or by directed
synthesis) compounds that are similar to the fragment (so-called
nearest-neighbour compounds). These compounds can then
establish which compound(s) are suitable for structure-guided
fragment to lead optimisation.
Recently, we have developed an additional approach for opti-
misation of fragments to hits and subsequently to lead
compounds19,20, which has also been exploited by others21. For a
simple one-step dissociation process, the thermodynamics and
kinetics of ligand (L) association with a protein (P) can be
represented as in Eqs. (1) and (2)
PL !
kon
koff
Pþ L ð1Þ
KD ¼
koff
kon
¼
½P ½L
½PL
; ð2Þ
where KD is the equilibrium dissociation constant (often referred
to as affinity) and koff and kon are the kinetic off and on rates of
binding, respectively. It is our observation that improvements in
affinity during hit optimisation are usually through a slower koff
or off-rate, as observed and exploited by others22. This rate is
independent of concentration, and as we confirm in this paper, is
a valid surrogate for measurement of affinity.
The process of hit optimisation in a drug discovery project
requires a significant amount of time and resource in compound
synthesis and purification followed by preparation of a solution of
known concentration to assay for compound activity. This is
particularly onerous in the early stages of discovery where many
compounds may be synthesised to identify how to improve the
affinity of binding by variation of substituents. We realised that
the concentration independence of the off-rate could be exploited
to speed up the efficiency and speed of compound optimisation.
Changes in off-rate can be measured by SPR for a mixture where
a starting material has been reacted with a second reagent without
purification (so-called crude reaction mixture (CRM)) if the
reaction has generated some product. This approach can be
readily scaled to plate-based format, where the starting material is
reacted with a different second reagent in each well of the plate.
Provided there is no interference from the other reagents in the
reaction, this significantly increases the speed, reduces chemical
waste and lowers the cost of initial SAR exploration.
In this paper, we investigate how high-throughput crystal
structure determination on the XChem platform (controlled by
XChemExplorer, XCE23) can be used with CRMs and combined
with SPR in hit optimisation. The results of experiments are
described for two targets, the N-terminal ATPase domain of heat
shock protein 90α (aa9–236), hereafter referred to as Hsp90 and
pyruvate dehydrogenase kinase 2 (aa16-407), hereafter referred to
as PDHK2, both members of the GHKL family of ATPases for
which we have previously identified a series of potent
inhibitors13,14,24,25. The initial experiments establish optimal
soaking conditions for crystal structure determination. We then
analyse the diffraction data for crystals of both PDHK2 and
Hsp90 soaked with CRMs, and compare the results to the off-
rates determined by SPR. The results suggest a protocol for such
hit optimisation and identify issues to be considered in experi-
ment design.
Results
Crude reaction mixtures. Two starting materials were selected for
the experiments reported here: 1 is a resorcinol fragment hit
(SM1) and 2 (SM2), a hit compound evolved from 1. These were
chosen as representing hits with relatively fast (1) and slow (2) koff
rates: 1 has a fast koff at the limit of sensitivity of SPR of more than
1 s−1 for both targets; 2 has a slower koff for PDHK2 (0.083 s−1)
than for Hsp90 (0.2 s−1).
Figure 1 shows the crystal structure of SM1 and SM2 bound to
Hsp90 and PDHK2. For both proteins, the main interaction of
the resorcinol core is with a solvent network around the acid
moiety (D93 for Hsp90; D282 for PDHK2), and there are many
similarities in the nature and geometry of the amino acids that
interact with this core. The nitrogen of the SM1 amide provides a
vector into solvent where the amino acids are different between
the two proteins. It is this vector for which the CRMs were
designed to explore in a fragment-growing approach, maintaining
the interactions made by the resorcinol moiety in both SM1 and
SM2.
Eighty-three different CRMs were prepared as described in our
earlier publication20 with the reaction scheme as summarised in
Fig. 2 and in Supplementary Methods.
The CRMs were constructed through synthesis of the relevant
two acid chloride intermediates with a protected resorcinol,
which were then coupled with a selection of amines to give 55 and
28 CRMs with SM1 and SM2 as the starting material, respectively.
Supplementary Table 1 contains the chemical structures for the
starting material and expected product for all the CRMs used in
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these experiments. The yields of product in the CRMs were
determined by LCMS. This table also includes the results of
analyses of crystal diffraction data from these samples soaked into
Hsp90 or PDHK2 apo crystals that will be described and
discussed below.
The expectation was that soaking crystals with the CRMs
would give a native structure, the respective starting material or
the expected product of the reaction bound to the protein. In the
following description of the experiments and results, the terms
“SM” and “PR” signify that the electron density determined for a
crystal soaked with a CRM was interpreted as having,
respectively, the starting material or the product bound. “N” is
for a native structure. These terms, SM and PR, are used
extensively in the following presentation of “Results” and
“Discussion”.
Establishing and validating crystal-soaking protocols. The first
set of experiments were to optimise the crystal preparation and
soaking protocols for the two proteins. The XChem facility
requires crystals in triple-drop mosquito sitting-drop plates26.
Our previous projects on the two proteins used crystals grown in
hanging drops. In preliminary experiments (data not shown),
PDHK2 crystals could be grown in sitting drops, diffracted and
were suitable for compound soaking and withstood 10% DMSO
in the crystallisation medium. However, Hsp90 crystals grown in
sitting drops could not tolerate DMSO and did not diffract when
soaked with compounds for unknown reasons. Hsp90 crystals
were therefore generated in hanging drops and transferred
manually to sitting drops for the XChem robotic systems.
The details of crystallisation, the XChem process and software
protocols used for structure determination and refinement for
both manual and automatic refinement with the PanDDA12
system at XChem are described in the “Methods” section. The
rationale for performing all crystal-soaking experiments in
triplicate is described in Supplementary Note 1.
A series of experiments were performed varying soaking time
and concentration of the compound for crystals of
PDHK2 soaked with 13 CRMs (indicated in Supplementary
Table 1) and the corresponding 13 purified products (compounds
1 and 11–22, see Supplementary Fig. 1). Crystals were soaked in
triplicate for 4 h, overnight and 2 days with a final concentration
of 2 mM of compound (final concentration of 10% DMSO) before
diffraction data were collected for the total of 234 crystals on the
XChem pipeline, and the diffraction data processed manually.
The criteria for success were obtaining electron density for a
Hsp90
PDHK2
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Fig. 1 Crystal structures of the starting materials bound to the two proteins. Shown are the compounds (magenta carbon atoms) and water molecules
and amino acids from the proteins that are within 3.5 Å of the compound (with green carbon atoms) and with red oxygen, blue nitrogen and yellow sulfur
atoms. 2Fo–Fc electron density contoured at 1σ for the ligand is shown in dark blue (see Supplementary Fig. 6 for omit maps); hydrogen bonding between
ligand, protein and solvent is shown with black dashed lines; pdb code and resolution shown for each structure.
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compound (either product or starting material in the case of the
CRM soaks) bound to the protein. For a 2-day soak at 2 mM, 10%
of the 234 datasets were unusable due to system failure or poorly
diffracting crystals—there was little variation in failure rate with
4 h and overnight soaking (8% and 13%, respectively). A
compound was identified as binding for 95%, 92% and 94% of
the usable datasets for 4 h, overnight and 2-day soaks,
respectively, for the CRMs, and 96%, 94% and 94% for the
purified compounds. There was a slight degradation in resolution
by using increased soaking times (see Supplementary Fig. 2), but
the electron density for some compounds was stronger for the
longer-time soak (an example is shown in Supplementary Fig. 3
for both a CRM and a purified compound). A 2-day soak time
was therefore used in all subsequent experiments. The results
with 2 mM compound in the soaking experiment were compared
with 1 mM and 0.5 mM final compound concentration, all after a
2-day soak (data not shown). There was no improvement in
resolution with 1 mM final compound concentration, and there
were fewer bound structures when the crystals were soaked at
0.5 mM of CRM.
This soaking protocol (2 mM for 2 days) had been successfully
used for Hsp90 crystals previously, so a smaller number of
control experiments were carried out to confirm that this protocol
was suitable for Hsp90 in the XChem system. Data were collected
on single samples for six of the CRMs (as marked in
Supplementary Table 1) and two of the expected purified
compounds. Compounds were observed in all the datasets
collected. The 2 mM for 2-day soaking protocol was used for
both proteins for all subsequent experiments.
The datasets from the control experiments were also processed
automatically using the PanDDA software12 (see “Methods” for
protocols). PanDDA identifies a binding event by comparison of
an electron-density map with an average map built from a
selection of the datasets provided. This is successful for fragment
screening, as the hit rate (a fragment binding to a particular site of
the protein) is low (0–5%), and so the average map built by
PanDDA represents an empty binding site. For our experiments,
the hit rate increases, which results in more density in the binding
site for the average map, which means PanDDA is less able to
correctly identify a binding event. A modified protocol was used
for the full screen, where 40 datasets were provided from crystals
soaked with the screen solvent, DMSO. These “blank” datasets
were used to build the PanDDA mean map, improving the
contrast with the maps obtained from crystals with soaked
compounds.
In the case of PDHK2, there was also an issue with the
resolution of some of the data sets that were at the limit of where
PanDDA can be effective (around 3.0 Å). In addition, the
elaboration from SM2 can result in a disordered portion of the
compound out into solvent (see, e.g., the electron-density maps
shown in Supplementary Fig. 4). For Hsp90, issues also arose
because different protein conformations can be found for
different ligands27. Improvements were made in the protocols
for using PanDDA (described in “Methods”), and all the results
presented in this paper from PanDDA are with this improved
protocol.
Having established the soaking conditions, the full set of 83
CRMs were soaked in triplicate into crystals of PDHK2 and
Hsp90 at 2 mM for 2 days, and diffraction data collected on all
498 (83 × 3 × 2) crystals in a single dataset-collection session. The
results are summarised in Supplementary Table 1 and
discussed below.
XChem performance and comparing PanDDA with manual fit
of electron density. When establishing the soaking protocol
(described in the previous section), we had determined the
structure of the purified compound in PDHK2 for 13 products
from 83 CRMs. For the corresponding CRM, PR was seen for 11
of the compounds and SM for 2—although these were both
CRMs with low product yield (<10%). From this, we conclude
that soaking with a CRM finds most of the PR structures for
PDHK2. For Hsp90, there were only two purified compounds for
which structures had previously been determined (as marked in
Supplementary Table 1), and PR was seen for only one of these
from the corresponding CRM.
Fig. 2 Reaction scheme for 55 and 28 crude reaction mixtures (CRMs) generated from SM1 and SM2. Reagents and conditions: a Ac2O, c H2SO4, 65 °C,
30min, 80%; b i. (COCl)2, DMF (cat.), DCM, rt 2 h; ii. R1R2NH, Et3N, DCM, rt, 26 h; iii. NH3 (7 N in MeOH, rt, 48 h); c BnBr, K2CO3, DMF, rt, 1 h; d i. 4,
(COCl)2, DMF (cat.), rt, 1.5 h; ii. 6, Et3N, DCM, 0 °C → rt, 1.5 h, 94% (from 5); e H2, 10% Pd/C, EtOAc, rt, 2 h, 66%.
ARTICLE COMMUNICATIONS CHEMISTRY | https://doi.org/10.1038/s42004-020-00367-0
4 COMMUNICATIONS CHEMISTRY |           (2020) 3:122 | https://doi.org/10.1038/s42004-020-00367-0 | www.nature.com/commschem
The electron-density maps generated for the triplicate soaks of
83 CRMs into PDHK2 and Hsp90 crystals were analysed
manually and using the automated protocols of the PanDDA
software. These results are summarised in the central columns of
Supplementary Table 1 (columns 8–13 and 15–20). Each CRM
contains varying amounts of product or starting material,
depending on the degree of completion of the reaction, but the
combined amount of product and starting material is high and
approximately the same for each CRM, so if crystal soaking is
successful, then a compound should be seen bound in every
crystal.
The first feature of the results is that out of 498 different
experiments, only 11 N was seen for PDHK2 and 43 N for
Hsp90. There were only four CRM triplicates for Hsp90 (and
none for PDHK2) where only N was seen—all others had at
least 1 PR or 1 SM. This confirms that the soaking protocol
chosen for both proteins was appropriate for the full set of
CRMs, giving a success rate (compound bound) much higher
than historically obtained (Supplementary Note 1) for the
targets, probably because the starting materials consistently
gave bound structures.
PanDDA and manual fitting find at least 1 PR in 50 of 83
CRMs for PDHK2 and 29 of 83 CRMs for Hsp90. The
consistency of the results between PanDDA and manual fitting
is illustrated in Table 1, which summarises for how many CRMs
the number of PR or SM seen for either target is found using
either PanDDA or manual fitting method.
These results illustrate firstly that success was maintained in
the soaking and data collection for this larger set of samples, and
secondly that PanDDA (after the improvements described in
“Methods”) and manual fitting find approximately the same
number of PR and SM. The main discrepancy is the number of
PR for PDHK2—which as discussed in the section establishing
the protocols (and shown in Supplementary Fig. 4) is mainly due
to low resolution of some of the datasets and disordered density
as the compound is extended into solvent. This effect was
compounded by the choice of dataset submitted to PanDDA by
the automated pipeline XCE23. PR was fitted more often when the
electron-density maps were fitted and refined manually.
Treatment of the results from triplicate experiments. The
results from the triplicate soaking experiments were often not
consistent. For example, although there were 63 CRMs where
both PanDDA and manual find the same number of SMs for
PDHK2, there were only 19 samples where the triplicate gave 3
SMs from PanDDA and 22 samples where the triplicate gave 3
SMs from manual fitting. As the aim of the experiments is to
assess the value of the automated protocols of XChem at iden-
tifying opportunities for hit optimisation, the results were treated
as follows:
● The results from PanDDA fitting were used alone.
● If the electron density is poor or there was mechanical or
crystal failure, then the result is N.
● Where there is at least 1 PR in the triplicate, then the
result is PR.
● Where there is no PR but at least 1 SM, the result is SM.
● Otherwise the result is N.
All reference to PR, SM and N in the following analysis is from
this treatment.
Off-rate for the CRMs. The off-rate or koff for dissociation of
each of the 83 CRMs from Hsp90 and PDHK2 was measured in
duplicate by SPR and is shown in Supplementary Table 1. Failure
to obtain a koff value for some CRMs (not determined, ND) was
due to poor signal and was most marked for PDHK2.
The first analysis is to determine whether the XChem result can
provide information in the absence of affinity data. Figure 3
shows a plot of 1/koff (proportional to affinity) for those CRMs
with a yield above 10% that gave either an SM or PR structure for
the two targets.
The plots in Fig. 3 emphasise three points. The first is that the
compounds exhibit a slower koff and thus higher affinity for
Hsp90 than for PDHK2. The second is that PDHK2 gives PR
more often than SM. The final observation is that SM is obtained
for many of the slower koff compounds for Hsp90 and PR for
many of the faster koff compounds for PDHK2, so there would be
many false positives and false negatives if only the crystal
structure was used to guide compound optimisation. As shown in
Supplementary Fig. 5b, there is a suggestion that for Hsp90, the
crystals are selecting starting material for products with more
rotatable bonds, even though the product has a slower koff, but
this is not a significant effect.
Table 1 Fitting of electron density by PanDDA or manually gives similar results.
No of PR agrees PanDDA more PR
than manual
PanDDA less PR
than manual
No of SM agrees No with >0
PR PanDDA
No with >0
PR manual
PDHK2 62 6 15 63 55 53
Hsp90 68 15 0 63 36 29
Comparison of the results from PanDDA and manual fitting of diffraction data from the different CRMs soaked into both PDHK2 and Hsp90 crystals.
(b) Hsp90
PR      SM
(a)  PDHK2
PR     SM
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Fig. 3 The XChem result does not correlate with affinity of the product.
1/koff (where determined and capped at 40 in the plot) for those crude
reaction mixtures (CRMs) that gave a product in yield > 10% with a PR or
SM for each of (a) PDHK2 (blue PR, 1/koff= 5.0+ /−4.9; orange SM,
1/koff= 5.4+ /−4.7) and b Hsp90 (grey PR, 1/koff= 16.4+ /−16.6; orange
SM, 1/koff= 25.1+ /−39.8). Values are mean+ /− standard deviation.
Statistical analysis in Supplementary Fig. 5a.
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A more complete analysis of the results of Supplementary
Table 1 is to separately consider the CRMs for the two different
starting materials, as SM1 has a faster koff than SM2. Table 2
summarises the results, separated on starting material and the
measured koff for the two targets. If the koff for the product in the
CRM is slower (higher affinity) than the starting material, then
PR is a true positive and SM a false negative; if the koff for the
product in the CRM is faster or equal (weaker affinity) than the
starting material, then SM is a true negative and PR a false
positive. Figure 4 reorganises the results into true and false
positives and true and false negatives.
The cases where there are five or fewer examples are not
discussed further—this rate of false positives and false negatives is
to be expected in a high-throughput experiment. Figure 4
emphasises two issues—the high number of false positives seen
for PDHK2 and the high number of false negatives seen for
Hsp90. These are analysed further.
For PDHK2—16 of the 21 CRMs generating a product with koff
equal to or faster than for SM1 gave PR and only five gave SM.
This is not as expected as the product is as weak or weaker at
binding to PDHK2 than the starting material, and PDHK2 was in
general more reliable for crystal soaking. This does not appear to
be related to yield as 7 of these 16 CRMs that give PR have yields
below 20%, so there should be enough SM1 available. A possible
explanation for some of these results is that SM1 has a much
weaker binding than the products in these cases. The koff
measurements are at the limits of sensitivity of SPR, and any koff
faster than 1 s−1 was set to 1 s−1. However, if the CRMs are also
profiled by SPR, such false positives can readily be identified.
For Hsp90—14 of the 21 CRMs generating a product with
slower koff than SM2 gave a structure of the starting material. This
is not as expected as the product is binding with higher affinity
than the starting material. The yield was >40% for all seven of the
cases where PR was seen. Eight of the 14 cases where SM was seen
had product yield <10%. The products for the other six CRMs
with yield >10% that gave SM have a predicted solubility of close
to zero. The number of false negatives from the CRMs from SM2
could therefore be due to either low yield or poor solubility of the
product formed.
The other anomaly for Hsp90 cannot be fully explained.
Twenty-two of 48 CRMs generating a product with slower koff
than SM1 gave SM. This is not as expected as the product binds
with higher affinity than the starting material. This could either
be related to yield as this was less than 10% for 9 of the 22 CRMs
or it could be due to low solubility—the product for 9 of the 11
remaining CRMs with yield above 10% has predicted solubility of
less than 1 mM. Therefore, the false negatives in this case can be
explained by solubility or yield. However, low solubility or yield is
not always a predictor of whether SM is observed instead of PR.
Eight of the 26 CRMs that gave a PR also had less than 10% yield,
and the product for 15 of these 26 CRMs has predicted solubility
of less than 1mM. However, it should be noted that the
determination of yield by automated LCMS is not fully reliable,
particularly for compounds with poor solubility.
There is one example that illustrates the influence of product
yield in the CRM. CRM numbers 32 and 44 are duplicates—
however, the yield for CRM 32 was much higher (43%) than that
for CRM 44 (2%). This can explain the observed kinetics—for
CRM 44, the koff is that of the starting material. The amount of
product is also reflected in the number of PR and SM seen. All
three of the triplicate crystals for CRM 32 gave PR for PDHK2,
and two of the triplicates gave PR for Hsp90, whereas only one of
the crystals for CRM 44 gave PR for PDHK2 and none for Hsp90.
Is there an explanation for the significant anomaly for
Hsp90 samples? The above analysis highlights that Hsp90 gave
many false negative results. This is where SM is seen when it
should have been PR from CRMs that give a good yield of a
product with a slower koff than the starting material. There are
four possible reasons why these compounds did not give PR—
solubility of the product in the crystallisation conditions, there
was an error in measuring koff by SPR, the product does not soak
into native Hsp90 crystals or the CRM had some influence on
product binding to Hsp90 in the crystal. Purified compounds
were available for some of these CRMs, and for this subset, there
are two cases. The first is where PR is seen for PDHK2 from the
same CRM, suggesting that it is not an issue of solubility; this is
for CRM numbers 2, 11, 15 and 63. The second case is where SM
is seen for PDHK2 (mostly explained by koff being faster than the
starting material for PDHK2), but SM is also seen for Hsp90
where the koff is slower than the starting material. This is for
CRMs 57, 68, 72, 75 and 83. CRMs 2, 11 and 15 are from SM1;
the remainder are from the relatively slower koff SM2.
Table 3 summarises for each of the purified compounds from
these nine CRMs, the results of a manual soaking of the purified
compound or the CRM into Hsp90 crystals, and the measurement
for the purified compounds of solubility and KD measured by both
SPR titration and by isothermal titration calorimetry (ITC). A
crystal structure of product was seen for eight of the nine purified
compounds (not for the product of CRM 11 which had low
solubility), and one of the CRMs gave PR on manual soaking
Table 2 Analysis of results.
PDHK2d Hsp90e
koff No PR No SM No PR No SM
CRM
from
SM1a
Fasterc 16 5 2 1
Slower 19 3 26 22
CRM
from
SM2b
Fasterc 9 14 3 4
Slower 2 2 7 14
The table shows the number of PR and SM for each target for the CRMs from the two starting
materials where the product gave a faster (or equal) or slower koff than the starting material.
aThere are 55 CRMs from SM1; for Hsp90, two gave native structures.
bThere are 28 CRMs from SM2.
cFaster or equal to koff for the starting material.
dkoff was not determined for 12 CRMs from SM1 and 1 CRM from SM2 for PDHK2.
ekoff was not determined for two CRMs from SM1 for Hsp90.
19
16
9
TRUE FALSE TRUE FALSE
21
25
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5
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(PR)
NEGATIVES 
(SM)
5
3
14
26
3
7
TRUE FALSE TRUE FALSE
33
5
5
36
POSITIVES 
(PR)
NEGATIVES 
(SM)
22
14
4
PDHK2 Hsp90
SM2
SM1
Fig. 4 Analysis of the results. The data of Table 2 plotted to emphasise the
number of true and false positives and true and false negatives obtained.
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(CRM 2). This leaves anomalies for seven CRMs that gave SM. One
of these had low solubility (CRM 75), leaving six CRMs giving SM
on repeated manual soaking to explain.
For two of the CRMs (68 and 72), the more accurate
measurement of KD by titration in SPR shows that the product
has about the same affinity as the starting material. The koff values
measured in high throughput for the CRMs were similar to the
starting material (0.12 s−1 for both CRMs versus 0.2 s−1 for SM2),
suggesting hat a larger threshold should be used to define a slower
koff.. Of the remaining four (CRMs 15, 63, 57 and 83), three had
<10% yield of product, which may be the explanation why SM was
obtained. Taking into account the contributions of solubility and
product yield to the likelihood of obtaining PR, the results are
reasonably consistent for such a high-throughput experiment.
Discriminating between eutomer and distomer. CRM number
11 is a racemate of two enantiomers, 23 and 24. In a series of
control experiments, purified samples of each of the separate
enantiomers were soaked (2 days, 2 mM) into PDHK2 crystals,
and as shown in Fig. 5, structures were obtained for both the
eutomer (23, Kd= 0.14 µM determined by FP assay) and dis-
tomer (24, Kd= 17 µM). A PR was obtained for all three of the
Table 3 Binding of ligands from crude reaction mixtures (CRMs) in Hsp90 crystals is not related to affinity.
CRM no Solubility of
pure (µM)
Result soak
of pure
Result soak
of CRM
koff
CRM (s−1)
Yield (%) HAC nRot KD (SPR) (µM)
of pure
KD (ITC) (µM)
of pure
2 400 Bound PR 0.1 8 22 1 1.0 0.65
11 24 Native SM1 0.23 34 30 4 17 ND
15 440 Bound SM1 0.06 1 20 3 0.07 0.36
63 460 Bound SM2 0.012 9 33 4 0.04 0.07
57 320 Bound SM2 0.03 39 32 3 0.71 0.26
68 350 Bound SM2 0.12 9 29 4 3.0 ND
72 300 Bound SM2 0.12 8 30 6 1.7 3.3
75 7 Bound SM2 0.013 3 30 3 0.019 ND
83 370 Bound SM2 0.05 8 31 6 0.36 0.29
SM1 >1 2000
SM2 0.2 2
The results for measuring solubility at pH 7.4 and affinity and manual crystal structure determination for selected CRMs and associated purified products. Solubility, SPR and ITC measurements were
made at 25 °C. SPR measurements are an average of at least two determinations; ITC and solubility are a single measurement. ND in ITC was due to lack of heat observed.
(a). Pure Eutomer 23
(c). CRM11 -
(b). Pure Distomer 24
6TMP    2.08Å 6TMQ
2.11Å
6TMZ    2.71Å
Best structure from triplicate
OH
HO
NO
O
O
N
*
* R = 23, S = 24
Fig. 5 Crystal selects the most potent enantiomer from a mixture. Details from the crystal structures of a eutomer 23, b distomer 24 and c crude reaction
mixture (CRM) number 11 bound to PDHK2. PDB code and resolution are shown. See the legend to Fig. 1 for details of atom selection and representation.
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soaks of CRM number 11 in the full XChem screen that selected
just the higher-affinity eutomer 23.
Discussion
The screening of CRMs can increase the efficiency of early hit
exploration in drug discovery. The time-saving and reagent effi-
ciency will vary with reaction chemistry, but the reactions
reported here for 83 CRMs took ~5 FTE days to set up and
analyse, compared to an estimate of 15–20 FTE days for pre-
paration, purification, characterisation and preparation of sepa-
rate stock solution for each of the samples, additionally saving
35–50 litres of various solvents for workup and purification, and
approximately sevenfold saving of reagents and solvents for
synthetic operations (detailed calculation in Supplementary
Note 2).
The objective of this study was to investigate how the
streamlined sample handling, data collection and processing of
the high-throughput structure determination facility, XChem at
the Diamond Light Source, UK synchrotron, can be used to
screen such CRMs containing compounds that explore how to
grow from one vector of a fragment hit to a more potent lead
compound. As with any high-throughput experimental approach,
there are false positives and false negatives. The data collected
were able to identify these and the reasons for discrepancies
explored.
The optimal conditions for obtaining soaked crystal structures
of compounds bound to the two test proteins, Hsp90 and
PDHK2, were established in control experiments. This also
established that the automated processing by the PanDDA soft-
ware (with suitable modifications to the protocol) was as reliable
as manual fitting at identifying the bound compound in the
electron density. Most of the analysis therefore focussed on the
results from PanDDA as it enables the rapid analysis of a large
number of crystallographic datasets.
The experiments reported here were performed in triplicate,
and as described above, the result classified as the product bound
to the protein (PR) if any of the triplicates gave PR, as the starting
material bound to the protein (SM) if there was no PR in the
triplicates but an SM, and native (N) if no result was obtained for
any of the triplicates. The main objective of soaking the CRM into
a crystal is to obtain the structure of a product bound to the
protein to inform structure-based compound optimisation.
Table 4 summarises the different results obtained if just the first
(or first two) experiment(s) of the triplicate is considered. For
PDHK2, taking just the first result would have given 34 PR
instead of 55, and for Hsp90, 30 PR instead of 36. For the other 15
CRMs for PDHK2 (6 for Hsp90), the first experiment was
recorded sometimes as SM, but predominantly as N because of
some failure of the crystal, data collection or processing; for these
cases, the duplicate would have improved the results. It is
therefore a balance of resources available compared to the value
of completeness of the data obtained in deciding how many
repeats to perform for each experiment.
The central premise of assessing CRMs by SPR is that the
measured off-rate, koff, is a surrogate for affinity, such that slower
koff reflects higher affinity. This is confirmed for some examples
in the results shown in Table 3 above. SM1 has a KD of 2 mM
measured by ITC for binding to Hsp90 with a very fast off-rate
(koff > 1 s−1) by SPR. The purified compounds from the CRMs 2,
11, 15 and 55 all have slower koff by SPR and higher affinity as
measured by ITC.
The CRMs contain both starting material and product, and the
expectation was that the product would be bound where it had a
higher affinity and the starting material where the modification
reduced the affinity. One clear result from the experiments was
that the crystal can select the highest-affinity enantiomer from a
racemic mixture within the CRM, which confirms this principle.
In about a half of the examples (Table 2), the results were as
expected. There were indications that in other examples, the
product yield may be the issue. For example, there were just four
examples where only native structures were obtained for Hsp90
from 83 CRMs (see Supplementary Table 1, CRM numbers 16,
26, 45 and 51). Two of these four CRMs contained no detectable
product, but did contain starting material (starting material was
also seen for these two CRMs for PDHK2). The other two CRMs
contained a good yield of product, and a product structure was
seen in PDHK2 suggesting good solubility, but nothing was seen
bound in Hsp90. More confounding was that for some CRMs, a
product-bound structure was observed even when the amount of
product generated was not detectable in the high-throughput
LCMS measurements, and in other cases, the product was seen
when SPR indicated that the product had a weaker affinity for the
protein than the starting material. The analysis was able to
identify a reason for some but not all these anomalies. Another
consideration is that the compounds could have different solu-
bility in the crystallisation systems, which is different from that of
the buffers used for SPR. It could also be that the kinetics and/or
thermodynamics of binding to a preformed crystal is affected by
the crystal packing in different ways for different compounds.
There is a suggestion (Supplementary Fig. 5b) that SM was seen
for larger products with a slower koff; however, the results with
purified compounds (Table 3) suggest that this is only when the
compound is in a CRM.
In conclusion, soaking a protein crystal with a CRM auto-
matically generated crystal structures for most (for PDHK2) or
many (for Hsp90) of the compounds generated in the reaction
that have an increased affinity for binding to the protein com-
pared to the starting material. For PDHK2, most of the false
positives and false negatives can be understood to arise from low
solubility or low yield of product compound. There was a higher
false-negative rate for Hsp90 where crystal structures were of the
starting material rather than the higher-affinity product. The
explanation for this anomaly is not clear, but is possibly related to
Table 4 Results obtained if we consider the singleton or duplicate experiment compared to the triplicate.
PDHK2 HSP90
Triplicate
result class
Number from
triplicate
Number from singleton
(duplicate)
Singleton/duplicate
result class
Number from singleton
(duplicate)
Number from
triplicate
N 0 4
SM 28 6 (2) N 6 (1) 43
22 (26) SM 37 (42)
PR 55 13 (5) N 5 (2) 36
2 (6) SM 1 (1)
34 (44) PR 30 (33)
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the size of the compounds that would not readily soak into
crystals in the conditions under which the XChem pipeline was
operated.
There are some obvious limitations in applying the lessons
learnt from this study to other optimisation projects. The results
are for two enzymes with similar active sites (though very dif-
ferent activities) and for a focussed class of compound. It may be
that other proteins, other compound classes (and optimisation
strategies) and reaction types will behave differently. However,
this exhaustive analysis suggests the following protocol:
1. Establish a suitable crystal form (and format) for soaking
with a high concentration of ligand in the XChem facility.
There can be surprising differences in the performance of
what appear to be identical crystals grown in different
formats (in the Hsp90 case sitting versus hanging drops).
2. Characterise how reproducibly the crystal system will
generate ligand-bound crystal structures using the XChem
protocols and PanDDA analysis system. Use several known
compounds of varying affinity and molecular dimensions.
3. Use XChem (or some other screening method followed by
crystal structure determination) to identify fragments that
bind, and which vectors are accessible (synthetically and as
revealed by the binding mode) for optimisation of the
fragment; if possible, use SPR or NMR to characterise
binding of the fragment and evolved fragments.
4. Construct CRM libraries from selected fragments (consider
the strength of binding of the starting material and likely
solubility of the product); measure the yield of the product
in each CRM by mass spectrometry.
5. Use XChem to determine the structures of crystals soaked
with CRMs. It is probably enough to perform these
screening experiments as singletons. If possible, normalise
the concentration of the CRM to compensate for any low
yield of the product.
6. Use SPR to characterise the koff of the CRMs.
7. Assess whether enough information for compound pro-
ducts is obtained that can guide hits to lead optimisation. If
XChem has not generated product-bound structures for
sufficient products where the measured koff from SPR is
slower, then the crystal soaking should be repeated for
selected CRMs, and if still not successful, consider re-
synthesis (purification) of the compound.
Using such a protocol will more rapidly generate structural
insights on which to design modifications to compounds to
improve affinity or other drug-like properties, thereby increasing
the speed and efficiency of the drug discovery process.
Methods
Protein production. Both proteins (human PDHK2 (residues 16–407) and N-
terminal domain of human Hsp90α (residues 1–236)) were expressed as an N-
terminal His tag fusion protein with a TEV protease cleavage in BL21 cells and
purified on a Ni2+ affinity followed by size-exclusion column, details as previously
described13,27. Uncleaved His-tagged variants were used in SPR experiments; tags
were removed for crystallisation.
Crystallisation. PDHK2 was mixed with the allosteric binding site compound Pfz3
(N-(2-aminoethyl)-2-(3-chloro-4-[(4-isopropylbenzyl) oxy]phenyl) acetamide);
Pfizer, Patent application: EP1247860, 1-304, 2002) at threefold molar excess before
being concentrated to 10 mg/ml. Crystallisation experiments were set up in sitting-
drop 96-well 3-drop Swissci plates (Molecular Dimensions Limited) using a
Mosquito crystal robot (TTP Labtech Ltd). The liganded Pdhk2 crystallised in
0.1 M sodium acetate, pH 5.8, and 0.125M MgCl2 at 4 °C within 48 h.
Hsp90, concentrated to 18.75 mg/ml, was crystallised in 10% PEG3350, 0.1 M
sodium cacodylate, pH 6.5, and 0.2 M MgCl2 using the hanging-drop vapour-
diffusion method at 4 °C. Again, crystals grew within 48 h. The crystals were
subsequently transferred into the correct format needed for the XChem robotic
systems by pipetting 500 nL of mother liquor containing at least one Hsp90 crystal
into each depression of a 96-well 3-drop Swissci plate. This was repeated until >300
Hsp90 crystal drops were available.
Crystal structure determination. All methodology details of the XChem
fragment-screening platform can be found on the XChem webpage that is acces-
sible from the Diamond Light Source homepage (https://www.diamond.ac.uk/
Instruments/Mx/Fragment-Screening/Methods-for-Fragment-Screening.html).
Details of individual parts of the platform have been published12,23,26.
The crystal drops for both proteins were first photographed using a RI1000
Formulatrix imager. Each image was ranked according to the presence and quality
of crystals by the TeXRank software. An ECHO acoustic liquid handler (Labcyte)
was used to transfer the CRMs/pure compounds to the crystal drops, aiming for an
area of the drop that would cause minimum disruption to the crystal, as
determined by visual inspection following the TeXRank step.
Control experiments for PDHK2 crystal structure determination. A final
concentration of 2 mM of each of the 13 CRMs and 17 pure compounds was added
into crystal drops of PDHK2 in triplicate for soak-time durations of 2–4 h, O/N
and 2 days at 4 °C. In addition, the final compound concentrations of 0.5 mM and
1 mM were added into PDHK2 crystal drops in triplicate, which were subsequently
left to soak for 2 days also at 4 °C. Glycerol was added as a cryoprotectant (at a final
concentration of 20%) by ECHO acoustic transfer shortly before mounting the
crystals in cryo-cooled pucks. All data were collected on beamline I04-1 in auto-
mated mode and autoprocessed using xia223.
Control experiments for Hsp90 crystal structure determination. The same
XChem equipment was used for the Hsp90 control experiments. However only six
of the PDHK2 CRMs and the equivalent purified compounds were added into
Hsp90 crystal drops at 2 mM for 2 days at 4 °C. The cryoprotectant (13% glycerol)
was added, and the crystals mounted, cryo-cooled and data collected as described
for the PDHK2-soaked crystals above.
Collecting diffraction data for soaks of 83 CRMs into PDHK2 and Hsp90
crystals. Following data analysis of the control experiments, the full set of 83
CRMs were soaked in triplicate into crystals of PDHK2 and Hsp90 at 2 mM for
2 days at 4 °C. The relevant cryoprotectants were added, crystals mounted and
cryo-cooled and data were collected as described above for the control experiments.
PanDDA analysis and improvements made to the PanDDA protocols. The
datasets were processed using PanDDA in XChemExplorer23. Structure solution by
molecular replacement was performed using previously determined apo structures
(Hsp90 PDBcode 1uyl27, PDHK2 PDBcode 2bu728) as the search models. The
PanDDA system compares the electron density for each dataset against an average
map to generate a so-called “event map”. This is inspected manually and the
appropriate ligand fitted; the system then continues to refine the structure and
report fitting statistics.
The XChem facility is primarily used for fragment screening on one target. The
average map used to identify ligand binding is built from all the datasets. This is
effective for fragment screening in which the hit rate (a fragment binding in a
particular site of the protein) is low (0–5%). In the experiments described here, the hit
rate increases, and the quality of the average map built by PanDDA, if the settings are
unchanged, becomes less sensitive as more datasets used to generate the average map
have bound ligands. The comparison between maps derived from crystals with ligand
bound and such a statistical model can miss binding events as the difference in
electron density is poorly defined. As a workaround (and protocol for a follow-up
screen), at least 43 (for Hsp90) and 88 (for PDHK2) datasets were collected that had
only been soaked with the screen solvent (e.g., DMSO) using the same volume of
solvent (e.g., 10% of the final total volume of the crystal drop). These datasets only are
selected to build the PanDDA statistical model. The event maps obtained from
soaking the follow-up compounds are much clearer, resulting in a competitive
PanDDA analysis. This new protocol was used in this study for both proteins.
In the semi-automated PanDDA analysis, the event map is inspected manually
to assign whether the dataset is native or is PR or SM. The ligand is then fitted
manually, and the PanDDA process continues to automatically refine the structure,
finally generating a 2Fo–Fc map that is passed to the CCP4 program EDSTATS29.
Supplementary Table 1 shows the real-space correlation coefficient for the ligand
on this map. Supplementary Note 3 also contains a description of preliminary
calculations, which demonstrate that the real-space correlation coefficient value
cannot be used automatically to assign SM or PR.
PanDDA settings. For PanDDA to build a statistical model allowing the detection
of all binding events, some datasets were filtered using the following two options
available on the PanDDA tab of XCE:
ignore_datasets: datasets that do not need to be analysed by PanDDA. Datasets
from crystals obtained from a different crystallisation method, soaked using
different parameters (crystal solvent and concentration), unsoaked controls.
Leaving these datasets would either prevent the PanDDA analysis to succeed, or
just reduce the quality of its output.
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exclude_from_characterisation: Datasets analysed but excluded from the set that
PanDDA can select to calculate the mean map and generate the statistical model.
All the crystals soaked with CRMs were excluded. Including these datasets that
have a high chance of containing a binding event would result in PanDDA
generating an average map of low quality, and a poor analysis.
Although the published paper recommends the use of at least 30 datasets for the
generation of a “complete” statistical model, more DMSO-only crystals were
soaked to allow for experimental error and resolution variations.
Manual analysis of crystallographic datasets. Structure solution, refinement and
initial electron-density map calculation for each of the datasets was carried out
within the CCP4 programme suite29, using scripts incorporating the molecular
replacement programme Phaser30 used to solve the structures, Refmac531 for
refinement and COOT32 for inspection of the electron-density maps. The data
collection and refinement statistics for the crystal structures shown in Figs. 1 and 5
are shown in Supplementary Table 2. The omit maps shown in Supplementary
Fig. 6 were calculated as Fobs–Fcalc, where Fobs was the observed structure factor for
diffraction from the protein–ligand complex, and Fcalc the calculated structure
factor for the refined model of the protein–ligand complex with the ligand and
active-site solvent removed.
Ligand fitting. The programme Grade (Global Phasing Ltd) was used to create
ligand PDB and geometry dictionary files in the PanDDA analysis, whereas
AceDRG33 was used in the manual analysis. In both, the PanDDA and manual
analysis compounds were fitted into the electron-density maps using COOT32.
Surface plasmon resonance. SPR experiments were conducted on T200 and T100
BIAcore instruments (GE Healthcare) at 25 °C. The His-tagged proteins were
immobilised on a series of S NTA chips, and the running buffer with 10 mM
HEPES, pH 7.4, 150 mM NaCl, 0.05% P-20, 0.025 mM EDTA and 1% DMSO was
used. The sensor surface was regenerated between cycles to eliminate any carryover
of protein and/or analyte. Details are as described previously19.
Isothermal titration calorimetry. ITC experiments were conducted at 25 °C by
titration of a stock sample of 100 µM compound onto a solution of 10 µM Hsp90 in
a GE ITC200 instrument.
Compound aqueous solubility. Test samples for each compound (500 µM, 2.5%
DMSO fc) were prepared in PBS (pH 7.4) and incubated overnight at room
temperature on a plate shaker. Standard samples for each compound were prepared
in 60:40 v/v methanol:PBS and also incubated overnight. All samples in PBS were
filtered prior to measuring UV absorbance in the wavelength range 250–500 nm.
Calibration lines were plotted for the standard samples for each compound using
absorbance at the wavelength with the largest signal, and solubility (µM) for the
test sample read from the calibration line. Data presented are the mean of three
values determined within the same experiment.
Statistical analysis. Two-sample Kolmogorov–Smirnoff tests34,35 were performed
in KNIME36 using the “Kolmogorov–Smirnoff Test” node at alpha= 0.1 to test the
null hypothesis that the SM and PR results for each target (HSP90 and PDHK2)
were from a different distribution for the relevant property (1/koff, HAC, nRot).
Notched boxplots were generated in KNIME using the “Notched Boxplot”
(JFreechart) node from the Vernalis KNIME Community contribution37. Notches
are centred on the median and show the 95% confidence interval of the median
(+/− 1.57 × IQR/sqrt of N). Notches may extend beyond the limits of the boxes for
small values of N or skewed distributions.
Data availability
PDB files containing refined coordinates of the structures presented in this paper are
deposited at the RCSB. For Hsp90, the codes are 1: 6TN4, 2: 6TN5. For PDHK2, the
codes are 1: 6TN0, 2: 6TN2, 23: 6TMP, 24: 6TMQ, CRM 11: 6TMZ. The authors will
release the atomic coordinates and experimental data upon article publication.
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